Teva CEO on decimated share price: "It's rational enough from a market point of view"

As the CEO of Israeli pharmaceutical company Teva, Kåre Schultz has some work ahead of him in order to convince the market there's light at the end of the tunnel.
Teva CEO Kåre Schultz | Photo: Lars Krabbe/ERH
Teva CEO Kåre Schultz | Photo: Lars Krabbe/ERH
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

There's no reason to be bitter about the plummeting share price of Israeli pharmaceutical company Teva, as it makes sense, according to CEO Kåre Schultz, who has not yet managed to generate value for the firm's hard-pressed shareholders.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading